Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.97 is 234% below its 5-year average of -1.19, near the low end of its 5-year range (-3.97–1.76).
364.33% below its 12-month average of -0.86.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.01.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 14 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T22:28:51.835Z. Historical observations retain their original dates. Historical series through 2025-08-06.
EARNINGS PER SHARE (EPS)
-3.97
EARNINGS PER SHARE (EPS) AVG TTM
-0.86
EARNINGS PER SHARE (EPS) AVG 3Y
-1.18
EARNINGS PER SHARE (EPS) AVG 5Y
-1.19
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-364.33%
CURRENT VS 3Y AVG
-237.87%
CURRENT VS 5Y AVG
-233.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Entrada Therapeutics, Inc.
Market Cap
$210.41M
Earnings Per Share (EPS)
-3.97
TTM Avg
-0.86
3Y Avg
-1.18
5Y Avg
-1.19
Market Cap
$209.91M
Earnings Per Share (EPS)
0.38
TTM Avg
0.11
3Y Avg
-0.10
5Y Avg
-0.19
Market Cap
$210.98M
Earnings Per Share (EPS)
-11.77
TTM Avg
-8.68
3Y Avg
-4.76
5Y Avg
-3.49
Market Cap
$208.31M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.27M
Earnings Per Share (EPS)
4.12
TTM Avg
3.49
3Y Avg
2.39
5Y Avg
2.00
Market Cap
$214.24M
Earnings Per Share (EPS)
0.19
TTM Avg
0.17
3Y Avg
0.00
5Y Avg
-0.12
Market Cap
$214.46M
Earnings Per Share (EPS)
-2.18
TTM Avg
-1.64
3Y Avg
-1.32
5Y Avg
-1.32
Market Cap
$205.80M
Earnings Per Share (EPS)
-1.12
TTM Avg
-1.34
3Y Avg
-1.96
5Y Avg
-3.41
Market Cap
$215.07M
Earnings Per Share (EPS)
N/A
TTM Avg
0.11
3Y Avg
0.08
5Y Avg
0.07
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | $210.41M | -3.97 | -0.86 | -1.18 | -1.19 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 0.38 | 0.11 | -0.10 | -0.19 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -11.77 | -8.68 | -4.76 | -3.49 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 4.12 | 3.49 | 2.39 | 2.00 |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 0.19 | 0.17 | 0.00 | -0.12 |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | -2.18 | -1.64 | -1.32 | -1.32 |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -1.12 | -1.34 | -1.96 | -3.41 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | 0.11 | 0.08 | 0.07 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -0.79 | -1.48 | -1.81 | -1.82 |
Trailing EPS (TTM)
$-3.97
Forward EPS (Est.)
$-3.88
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.47 |
| 2024-12-31 | 1.76 |
| 2023-12-31 | -0.20 |
| 2022-12-31 | -2.79 |
| 2021-12-31 | -1.60 |
| 2020-12-31 | -0.84 |
| 2019-12-31 | -4.44 |
